Bitcoin price today: rises to $116.5k on Trump 401k order, altcoins rally
Investing.com -- OneMedNet Corporation (NASDAQ:ONMD) stock gained 6% premarket after announcing a partnership with Inka Health Corp., a subsidiary of Onco-Innovations Limited (CBOE CA:ONCO), to develop external control arms for cancer therapy trials.
The collaboration will leverage OneMedNet’s patient data platform alongside Inka Health’s SynoGraph platform, which combines machine learning with causal inference methods. The initial focus will be on building and validating an external control arm for the Keynote-189 trial of pembrolizumab in non-small cell lung cancer.
External control arms serve as alternatives to traditional clinical trial control groups, potentially reducing development timelines and costs for pharmaceutical companies. The project aims to replicate clinical trial results using real-world data while adhering to regulatory standards from the FDA, European Medicines Agency, and National Institute for Health and Care Excellence.
"We selected Inka Health for this initiative because their methodological approach aligns perfectly with our vision for high-quality evidence generation," said Aaron Green, President and CEO of OneMedNet.
Paul Arora, Co-Founder of Inka Health, stated the project aims to "set a new bar for how external control arms can be built and trusted" using real-world patient data.
The companies plan to submit a scientific abstract on their findings to ISPOR Europe 2025. OneMedNet currently operates a network of over 1,750 healthcare sites through its iRWD platform, providing medical imaging and electronic health records data.
According to market research cited by the companies, the Real-World Evidence market is projected to exceed $4.6 billion globally by 2030.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.